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Abstract
Here we report the immunological characterization of lipid-polymer hybrid nanoparticles (NPs) and
propose a method to control the levels of complement activation induced by these NPs. This method
consists of the highly specific modification of the NP surface with methoxyl, carboxyl, and amine
groups. Hybrid NPs with methoxyl surface groups induced the lowest complement activation,
whereas the NPs with amine surface groups induced the highest activation. All possible combinations
among carboxyl, amine, and methoxyl groups also activated the complement system to a certain
extent. All types of NPs activated the complement system primarily via the alternative pathway rather
than the lectin pathway The classical pathway was activated to a very small extent by the NPs with
carboxyl and amine surface groups. Human serum and plasma protein binding studies showed that
these NPs had different protein binding patterns. Studies of both complement activation and
coagulation activation suggested that NPs with methoxyl surface groups might be an ideal candidate
for drug delivery applications, since they are not likely to cause any immunological adverse reaction
in the human body.
1. Introduction
Lipid-polymer hybrid nanoparticles (NPs) hold great promise as a drug delivery vehicle in the
treatment of various diseases. The NP is comprised of a hydrophobic polymeric core and a
hydrophilic polymeric shell separated by a lipid monolayer (Fig. 1A). [1] This type of hybrid
NP combines the merits of both liposomes and polymeric NPs, two of the most popular drug
delivery vehicles approved for clinical use. It has been shown in vitro that lipid-polymer hybrid
NPs have the advantages of carrying poorly water-soluble drugs with high encapsulation and
loading yields, tunable and sustained drug release profile, excellent serum stability, and
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differential targeting of cells. In addition to potential applications in drug delivery, the hybrid
NPs can also be used as novel adjuvants for vaccination.
However, the immunological properties of these lipid-polymer hybrid NPs have not yet been
systematically investigated. If these NPs are to be utilized for systemic drug delivery
applications or as adjuvants for vaccination, we must know more about their
immunocompatibility characteristics such as complement system activation, plasma and serum
protein binding properties, and coagulation cascade activation.
The complement system, part of the innate immune system, is a biochemical cascade in blood
for the recognition and clearance of foreign materials [2]. It consists of over 20 small proteins
and protein fragments. These proteins normally circulate in the blood as inactive zymogens.
When they are stimulated by a trigger or activator, the complement system is activated,
resulting in response and activation of the cell-killing membrane attack complex. The
complement system can be activated via three different pathways: the classical pathway, the
alternative pathway, and the lectin pathway. In the classical pathway, the activation is triggered
when protein C1q recognises activators and binds to their surface mainly via charges or
hydrophobic interactions [2–3]. The alternative pathway is activated by the covalent binding
of C3b to the hydroxyl or amino groups on the pathogen surface, and subsequent events leading
to complement activation are analogous to those in the classical pathway [2][4]. In the lectin
pathway the mannan-binding lectin (MBL) protein binds to activators through an interaction
with neutral sugar residues (e.g. mannose) [2]. Similarly L-ficolin can also initiate the lectin
pathway, but we know little about its recognition specificity.
Because reducing the complement system activation of a polymer’s surface is very important
for improving its blood compatibility, this subject has attracted much attention. Especially in
the 1980s and 1990s, there are many reports of various methods to diminish the activation of
the complement system. However, most methods involved complicated organic synthesis [5–
10] or other procedures impractical for translational research. The study of protein binding to
a material surface is also highly relevant to its immunocompatibility [11]. Bound proteins can
initiate thrombosis on the material surface by interacting with platelets or activating the
intrinsic clotting cascade[11]. Though there are many studies of human plasma protein binding
to various nanomaterials [12–22], only one paper in 1998 examined the binding of human
plasma proteins to polymeric NPs with different surface characteristics [23]. Martin et al.
reported the binding of human plasma proteins to five types of latex particles (diameter: 89 ±
35 nm to 660 ± 36 nm) surface-functionalized with a hydroxyl group, an ammonium group,
and a combination of the two groups. Martin et al. found remarkable differences of the types
and quantity of human plasma proteins that bind to those latex particles, complement system
activation experiments were not mentioned.
Here we report our systematic investigation of the immunocompatibility properties of lipid-
polymer hybrid NPs by measuring their complement system activation, human plasma protein
binding properties, and coagulation system activation at various surface chemistry
circumstances. In addition, though the focus of this work is the immunocompatibility properties
of lipid-polymer hybrid NPs, this study also provides a methodology to tune the surface
chemistry composition of new nanotherapeutic designs to screen for optimal nano-platforms
that have minimal immunogenicity.
2. Materials and Methods
2.1 Preparation of the nanoparticles
Poly (D, L-lactide-co-glycolide)-Lipid poly (ethylene glycol) nanoparticles (PLGA-Lipid-
PEG NPs) were prepared following a protocol described previously [1]. Briefly, PLGA
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polymer was dissolved in acetonitrile at a concentration of 2 mg/mL. The lipid lecithin (Alfa
Aesar) was mixed with 1, 2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Carboxy
(Polyethylene Glycol)2000] (DSPE-PEG-COOH)(Avanti Polar Lipids) at a molar ratio of
8.5:1.5 and dissolved in 4% ethanol aqueous solution. The total lipid weight (lecithin + DSPE-
PEG-COOH) was 15% of the PLGA polymer. The lipid solution was preheated at 65 °C for 3
minutes, and the PLGA solution was added dropwise under gentle stirring. The mixed solution
was vortexed vigorously for 3 minutes followed by gentle stirring for 2 hours at room
temperature. Finally the nanoparticles were washed three times using an Amicon Ultra-4
centrifugal filter (Millipore, Billerica, MA) with a molecular weight cutoff of 10K Da. The
same procedures were used to prepare the hybrid nanoparticles with other surface functional
groups or a mixture of surface groups.
2.2 Characterization of the lipid-polymer hybrid NPs
The NPs were suspended in 1X Phosphate Buffer Saline (PBS, pH=7.4). The hydrodynamic
diameter (nm) of the nanoparticles and their polydispersity index were determined from three
repeated experiments using dynamic light scattering with a Zeta Pals instrument (Brookhaven,
USA) at 25 °C. The Zeta potential (mV) of the nanoparticles was calculated from three repeated
measurements on a Zetasizer 2000 (Malvern Instruments, UK).
2.3 Complement System Activation studies
To assess complement system activation of the lipid-polymer hybrid nanoparticles in vitro,
three complement split products (SC5b-9, Bb, and 4cd) were analyzed using enzyme-linked
immunosorbent assay kits from Quidel Corp. (San Diego, CA, USA). SC5b-9 is the S-protein-
bound form of the terminal complex, a sensitive biomarker of C5a formation via both the
classical and the alternative pathways. Bb is the proteolytically active fragment of factor B, a
biomarker of complement system activation via the alternative pathway. C4d measures the
amount of the C4d-containing activation fragments of C4 (C4b, iC4b, and C4d), a biomarker
of complement system activation via the classical pathway. The nanoparticles were incubated
with human serum at a volume ratio of 1:5 in a shaking incubator (80 rpm) at 37°C for 1 hour.
After incubation the reaction was stopped by adding 60 times volume of PBS solution
containing 0.05 wt% Tween-20 protein stabilizers and 0.035 wt% ProClin 300. Complement
system activation of the nanoparticles was assayed following manufacturer’s instructions.
Zymosan was used as a positive control for the alternative pathway and terminal cascade.
Complement system activation via the lectin pathway was assessed using the ALPCO
Diagnostics kit (Salem, MA, USA).
To assess the genuine activation of the complement system via the alternative pathway, human
serum was diluted 1:1 by volume with Mg-EGTA buffer as described in [12]. The diluted
human serum was incubated with lipid-polymer nanoparticles and incubated for 1 hr at 37°C
in a shaking incubator. The reaction was stopped as described above.
The experiments described above were carried out in accordance with the ethical standards of
the responsible committee on human experimentation (institutional or regional) and with the
Helsinki Declaration of 1975, as revised in 1983.
2.4 Protein binding studies
Lipid-polymer hybrid NPs were incubated with the diluted (1:1 volume) human serum or
human plasma under gentle shaking of 80 rpm at 37°C for 1 hour. After incubation the NPs
were spun down using a microcentrifuge at 13,000 rpm for 15 min, and the supernatant was
removed. The same procedure was repeated 5 times. Next the NPs were reduced by 25 mM
DTT and heated for 10 min at 95° C. Then the NP samples were loaded and run through a
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gradient gel (4–12%) at 150 V for 70 min. The gel was stained with coomassie blue, and the
bands were analyzed by mass spectrometry (MIT Proteomics core facility).
2.5 Coagulation studies
Lipid-polymer hybrid NPs with methoxyl surface group (NP-OCH3) were incubated with fresh
human citrated plasma under gentle shaking (80 rpm) at 37 °C for 30 minutes. As negative
controls, NPs were incubated with human plasma and 1X PBS buffer in parallel. Triplicate
samples were prepared for each condition. After incubation, the samples were measured for
Prothrombin (PT), Activated Partial Thromboplastin Time (APTT), and Thrombin Time (TT).
These measurements were done by the Clinical Lab, Hematology section, at Brigham and
Women’s Hospital.
3. Results
3.1 Preparation and characterization of lipid-polymer hybrid NPs
Lipid-polymer hybrid NPs were prepared using a modified nanoprecipitation method as
described in section 2.1. As shown in Fig. 1A, the hybrid NPs are comprised of three
components: a hydrophobic poly(D,L-lactide-co-glycolide) (PLGA) core, a hydrophilic poly
(ethylene glycol) (PEG) shell, and a soybean phosphatidylcholine (lecithin) monolayer at the
interface of the hydrophobic core and hydrophilic shell. The PEG molecule is covalently
attached to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG), which is
interspersed throughout the lecithin monolayer By changing the end group of DSPE-PEG, the
NPs can be modified with different surface functional groups such as carboxyls, amines, and
methoxyls. In the present study, the NPs containing PLGA-lecithin-PEG-COOH, PLGA-
lecithin-PEG-NH2 and PLGA-lecithin-PEG-OCH3 are referred to as NP-COOH, NP-NH2, and
NP-OCH3, respectively.
Dynamic light scattering (DLS) was used to characterize NP hydrodynamic size (diameter,
nm) and surface zeta potential (mV) in each preparation. As shown in Fig. 1B, the average NP
size remained in the same range (89–110 nm) under our particular experimental conditions,
regardless of the surface functional groups. However, the surface zeta potential of NP-COOH,
NP-NH2, and NP-OCH3 are −25±1 mV, 10±2 mV, and −9±1 mV, respectively. All three NPs
were well-dispersed in 1X PBS buffer.
3.2 Human serum complement system activation by lipid-polymer hybrid NPs
After incubation with human serum, SC5b-9 concentration was measured to evaluate the
complement system activation of these NPs. As shown in Fig. 2A, it was found that lipid-
polymer hybrid NPs with an amine surface group (NP-NH2) more effectively activate the
complement system than NPs with carboxyl (NP-COOH) or methoxyl (NP-OCH3) surface
groups. However, all three NP formulations activate the complement system slightly more than
human serum (negative control) but significantly less than Zymosan (positive control), a well-
known complement system activator of the alternative pathway. Further studies found that
these NPs activate the alternative pathway (Fig. 2B) but not the lectin pathway (data not shown
here). As compared to human serum without any NPs (negative control), negligible
complement system activation via the classical pathway was noted for NP-COOH and NP-
NH2, and NP-OCH3 did not activate the classical pathway at all (Fig. 2C).
Complement components C6-8 precursors are proteins that participate in the formation of the
membrane attack complex, which leads to complement activation. The activation of the human
serum complement system via the classical pathway takes place when C1q, the recognition
subunit of the C1 complex, binds to complement activators. C1 binds to target ligands via the
globular domains or head groups, thereby triggering the activation of C1r and C1s, the proteases
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associated with C1q [3]. Since we found that binding occurred in the presence of Ca2+ ions
(Section 2.3), C1q would present as a C1 complex (C1qr2s2) in serum. Thus it appears that
the entire C1 binds to the hybrid NPs, activating C1s, which in turn cleaves C4 and C2 to
produce C4b. C4b then binds to complement activators via covalent bonds. It is possible that
C4b covalently binds to the carboxyl and amine groups on the NP surface. That would lead to
the formation of the C4b2a complex on the NP surface, resulting in C3 activation. The final
consequence of these processes is the activation of the complement system via the classical
pathway, as shown in Fig. 2C.
Fig. 2B shows that NP-NH2 activates the alternative pathway considerably more effectively
than NP-COOH or NP-OCH3. In particular, NP-OCH3 induced the lowest (negligible)
activation of the alternative pathway. Further studies found that Factor H, a main downregulator
of the alternative pathway, bound less effectively to NP-COOH than to NP-NH2 or NP-
OCH3 (Figs. 3B–4B and Table 1). Immunologically, less amount of factor H binding induces
higher level of complement system activation, consistent with the data in Fig. 2A–B and Table
1. One possible reason is that factor H and C3b compete for binding to the NPs, thereby
affecting NP complement activation. The high level of complement activation of NP-NH2
suggests C3b binds more strongly than Factor H to NPs. This idea is supported by the fact that
C3b covalently binds to NH2 and OH groups on the surface of the activator [4]. In addition,
the binding of other complement proteins such as C6 (Table 1) also indicates that the presence
of amine groups on the NP surface contributes to the high level of complement activation.
To investigate whether alternative pathway activation occurs independently and not as a
consequence of classical pathway activation, we used the Bb plus Quidel immuno assay kit.
The hybrid NPs were incubated with human serum in the presence of Mg2+ but not Ca2+, as
described in section 2.3. The absence of Ca2+ in this assay prevents classical pathway
activation, because the recognition complex of the classical pathway, C1qr2s2, is dissociated
and becomes inactive. The results confirm that alternative pathway activation occurs
independently and not as a consequence of classical pathway activation (data not shown). Since
alternative pathway activation relies on C3b binding to the activators, we expected that this
protein would bind to the surface of the hybrid NPs. Fig. 3B shows C3b β chain (~75 kDa) on
the NP surface (see next section for more details).
Figs. 3–5 demonstrates human serum complement system activation of lipid-polymer hybrid
NPs with a combination of surface functional groups, including carboxyl and methoxyl (NP-
COOH/OCH3), carboxyl and amine (NP-COOH/NH2), and amine and methoxyl (NP-NH2/
OCH3). For NP-COOH/OCH3 (Fig. 3A–B), more methoxyl groups on the NP surface decrease
the zeta potential (less negative) while reducing the level of complement activation of the NPs.
For example, when the molar ratio of COOH/OCH3(Fig. 3B) varied from 75/25 to 50/50 and
to 25/75, the NP surface zeta potential was approximately −23 mV, −21 mV, and −17 mV,
respectively, whereas the SC5b-9 concentration (Fig. 3A) decreased from 4287 ng/ml to 3298
ng/ml and to 3030 ng/ml. For NP-COOH/NH2 (Fig. 4A–B), different tendencies of NP surface
charge and complement activation were found. More amine groups on the NP surface result
in higher NP surface zeta potential (Fig. 4A) and higher complement activation (Fig. 4B). For
NP-NH2/OCH3 (Fig. 5A–B), we found that more methoxyl groups on the NP surface led to
lower NP surface zeta potential (Fig. 5A) and lower complement activation (Fig. 5B). These
results indicate that NPs with a combination of carboxyl, methoxyl, and amine groups produced
different levels of complement activation, probably resulting from the different physico-
chemical characteristics of the NPs. Table 2–4 showed that the amount of factor H and C3b
β chain proteins binding to the NP surface was correlated with the levels of complement
activation of the NPs. For example, factor H bound less effectively to the NP-COOH/NH2 with
a COOH/NH2molar ratio of 75/25 (Table 3) than to the NP-COOH/OCH3 with a COOH/
OCH3 molar ratio of 75/25 (Table 2). The highest level of C3bβ chain was found on the surface
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of NP-NH2/OCH3 (Table 4), which more complement activation than either NP-COOH/
OCH3 (Table 2) or NP-COOH/NH2 (Table 3).
3.3 Human serum and plasma proteins binding to lipid polymer hybrid NPs
We studied human serum and plasma protein binding to hybrid NPs with different surface
functional groups. Interestingly, we found that serum amyloid A-4 protein precursor
preferentially bound to NPs with surface amine and/or methoxyl groups, such as NP-OCH3
(Fig. 3B), NP-NH2 (Fig. 4B) and NP-NH2/OCH3 (Fig. 5B) The protein precursor did not bind
to NPs with carboxyl groups on the surface such as NP-COOH, NP-COOH/OCH3, and NP-
COOH/NH2. Together these observations indicate that binding of the serum amyloid A-4
protein to the NPs might be related to surface charge. This protein has been found abundantly
in the brains of schizofrenic patients. It would be interesting and worthwhile to further elucidate
the interaction and binding mechanisms of amyloid A-4 and NPs.
Determining how human plasma proteins bind to the lipid-polymer hybrid NPs is also
important, because it is closely related to the in vivo circulation half-life and biodistribution of
NPs. We found that human plasma and human serum had similar adsorption patterns on the
hybrid NPs, except for the binding of fibrinogen (Figs. 3–5B and 6). Fibrinogen α chain bound
less effectively to NP-COOH than to NP-OCH3 or NP-NH2 (Table 5). It was also found that
human plasma proteins with low molecular weight (such as the apolipoprotein family) bound
to the hybrid NPs (Figs. 6A–C). Fig. 6B shows that a small amount of factor H and complement
proteins C6, C8, and C1r bound to the NP-NH2/OCH3, but there was little binding of
apolipoprotein AI, serum amyloid A-4, or apolipoprotein C-III. However, all these proteins
bound to NP-COOH/NH2 with obvious absorption patterns (Fig. 6C) and to a lesser extent to
NP-COOH/OCH3 (Fig. 6A).
3.4 Coagulation studies of lipid-polymer hybrid NPs
Fibrinogen is one of the most abundant proteins in human plasma and requires special attention,
because it activates the coagulation cascade and plays a significant role in the opsonization
process of the complement system. To investigate whether NPs change fibrinogen’s effect on
human plasma clotting time, we chose NP-OCH3 for further immunocompatibility studies
because the hybrid NPs with methoxyl surface groups induced the lowest level of complement
activation. Coagulation assays including prothrombin time (PT), activated partial
thromboplastin time (APTT), and thrombin time (TT) were conducted with these NPs. PT
refers to the time that plasma takes to clot, which is a function of the extrinsic pathway; the
reference range is usually 12–15s [24]. The PT assay measures the presence of factors II, V,
VII, and X and fibrinogen. APTT measures the performance of the intrinsic and common
coagulation pathways. Thrombin converts fibrinogen to an active form that assembles into
fibrin and assures the success of the coagulation cascade. The results show that when human
plasma was incubated either with or without NP-OCH3, the addition of NPs has no effect on
clotting time. Only an insignificant change in APTT was noted in the presence of NP-OCH3.
Overall these coagulation assays suggest that hybrid NPs have no effect on the coagulation
system.
4. Discussion
4.1 NP preparation and characterization
The lipid-polymer hybrid NPs were prepared through a modified nanoprecipitation method
combined with self-assembly. This makes NP synthesis scalable and reproducible for clinical
manufacturing purposes. The hydrodynamic diameter of the NPs can be well-controlled within
the range of 50–200 nm by tuning the intrinsic parameters of NP formulation. This size range
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would allow the NPs to be used clinically as drug delivery vehicles. In addition, these NPs are
well-dispersed in and remain stable in 1X PBS buffer, human serum, and human plasma.
4.2 Complement system activation
In the 1990s, various types of pegylated polymeric NPs including poly (lactic-co-glycolic acid)
(PLGA) [13] [15][16] [17] and poly (D, L-lactide) (PLA) [19][22] were assessed for
complement activation. Those tests primarily involved hemolytic assays, a common and well-
accepted method among the scientific community. However, the recently developed
complement activation kits not only help to overcome some practical issues such as the partial
hydrolysis that the NPs might undergo during the assay, but also provide highly specific
quantitative analysis. For this reason Quidel Immunoassay kits were used.
It is well-known that the alternative pathway is activated when C3b protein is deposited onto
an activator surface containing amine or hydroxyl groups. However, the mechanism of
complement system activation via the alternative pathway is unpredictable, because it relies
on both charge and neutral sugars on the surface. On the other hand, the main recognition unit
of the classical pathway, C1q, usually binds to the activator surface through electrostatic and
hydrophobic interactions [3].
Our results at least partially agree with published literature on complement system activation,
since C3b covalently binds to the amine groups on the surface of NP-NH2. However we found
that NP-COOH and NP-OCH3 activate the human serum complement system primarily via the
alternative pathway. This disagrees with published findings that NP-COOH activates the
classical pathway because of the negative charge on the NPs. The poor activation of the
classical pathway suggests that, in competition with C1 complex or C1q to bind to the NP
surface, C3b binds dominantly. Another possible rationale is that NP-COOH and NP-OCH3
are taken as hydrophilic surface by C1q, which prevents the binding of C1q to the NPs.
Nevertheless, the levels of complement activation elicited these NPs are much lower than that
produced by Zymosan. Furthermore, the complement activation products C3b and iC3b derived
from the activation of C3 have an important medical role, because they act as adjuvants and
opsonins.
There is extensive literature on complement system activation of other nanomaterials such as
liposomes and polymeric NPs. It has been reported that positively charged liposomes
preferentially activate the alternative pathway, that negatively charged liposomes are likely to
activate the classical pathway, and that neutral liposomes are insensitive to complement system
activation [25]. Vittaz et al. [22] reported that PLA-PEG NPs consume very low amounts of
complement via the classical pathway when PEG coverage density is higher than 0.2 PEG
molecule per nm2. However the PLA-PEO NPs consume very high amounts of complement
via the classical pathway when the PEG coverage density is 0.19 PEG molecule per nm2.
Both the published literature and the results presented here indicate that several factors besides
surface charge and charge density, such as topographical accessibility of complement proteins
and excipients of the NP activators, determine complement system activation.
4.3 Serum and plasma protein binding
Over the last two decades, human serum and plasma protein binding to different nanomaterials
[10–22] including polymeric latex NPs[23], PLGA NPs[22], and carbon nanotubes [12] has
been extensively studied. Such studies have mainly focused on the apolipoprotein family (A-
IV, E, A-I, C-III), albumin, and fibrinogen on the nanomaterials’ surfaces. However the binding
of factor H has been observed only in chemically modified carbon nanotube systems [26] and
in the hybrid NP systems reported in this study. Factor H is the main downregulator of the
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alternative pathway in plasma, which consists of 20 short consensus repeat domains (SCRs),
each about 60 residues long [27]. The structure of FH modules 6–8 reveals multiple sulphated
sugar-binding sites [27]. In addition, the carboxyl-terminal region (SCRs 19–20, FH 19–20)
is unique configured to bind to C3b/C3d The heterogeneous intercalation of carboxyl,
methoxyl, and amine groups on the surface of the lipid-polymer hybrid NPs allows us to control
their surface chemistry and charge density, and in turn their human serum complement system
activation. Human serum and plasma protein binding studies identified the binding of two key
complement proteins, Factor H and C3b β chain, which play a pivotal role in the activation of
the complement system via the alternative pathway.
Amine groups on the surface of the NPs induced high levels of human serum complement
activation. However, a heterogeneous surface comprised of amine and methoxyl groups
activated the complement system even more effectively. Our results clearly demonstrate that
human serum factor H plays a very important role in complement activation, and that the
binding of factor H strongly depended on the charge and charge density of the NPs. Although
there is no strict correlation between the levels of complement activation and the amount of
factor H binding to the NP surface, factor H barely bound to NP-COOH. In addition, the protein
orientation of factor H on the NP surface might also affect activation of the complement system.
Our results showed that factor H attached to NP-NH2/OCH3 with high affinity, but we cannot
rule out the possibility that C3b and factor H might compete for binding sites. It is also likely
that SCR7-8 and/or 19-20 of Factor H [27–28] bound to NP-COOH and NP-OCH3, because
these domains have binding preference to negatively charged surfaces. Further studies should
be carried out to investigate this possibility. It is important to mention that the binding of human
plasma factor H to the lipid-polymer hybrid NPs was mediated by heparin in the present study.
It is well-known that heparin binds to factor H.
The complete sequestration of human serum factor H to these NPs could switch off the
activation of the complement system via the alternative pathway, thereby inhibiting
complement activation.
4. 4 Coagulation studies
It has been reported that fibrinogen binds to receptors expressed by cells of the mononuclear
phagocytic system [29]. However, results from coagulation studies of the lipid-polymer hybrid
NPs suggest that the binding of fibrinogen does not play a crucial role in those phenomena.
Thus, coagulation assays suggest that these NPs do not affect the coagulation cascade.
4.5 General comments
Here, studies of the immunocompatibility properties of lipid-polymer hybrid NPs with
heterogeneous surface functional groups (carboxyl, methoxyl, and amine) demonstrated that
the intercalation of various functional groups on the NP surface can precisely modulate the
activation of the human serum complement system. This method constitutes a powerful tool
that can help us understand the behavior of key complement proteins such as factor H and C3b
at the nanoscale level. This method could be also applied to other NP systems to understand
their complement activation properties.
5. Conclusions
Lipid-polymer hybrid NPs with heterogeneous surface functional groups (carboxyl, methoxyl,
and amine) have been systematically investigated for their immunocompatibility. It was found
that the NPs with methoxyl surface groups induced lower levels of complement activation
compared the NPs with carboxyl or amine surface groups. Coagulation studies demonstrated
that no hybrid NPs activated the coagulation cascade. Assays of both complement activation
Salvador-Morales et al. Page 8
Biomaterials. Author manuscript; available in PMC 2010 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and coagulation provide evidence of the good biocompatibility of these NPs, suggesting their
use in drug delivery to treat a myriad of diseases. In addition, our results reaffirm the idea that
NP surface chemistry significantly affects human plasma and serum protein adsorption
patterns. The heterogeneous intercalation of different surface functional groups on the NP
surface plays an important role in modulation of the complement system activation by
controlling the binding of key complement proteins such as Factor H and C3b.
A deeper understanding of how the key complement proteins interact with NPs will also help
us design new colloidal drug carriers and find efficient adjuvants for novel vaccines.
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Figure 1.
A) Schematic illustration of lipid-polymer hybrid nanoparticle (NP) bearing various surface
functional groups. The NP is comprised of a poly (D, L-lactide-co-glycolide) (PLGA) core, a
polyethylene glycol (PEG) shell and a lipid monolayer at the interface of the core and the shell.
The NP surface can be functionalized with one or a combination of carboxyl, methoxyl and
amine groups. B) Size and surface ζ potential of functionalized lipid-polymer hybrid NPs. The
size of these NPs is similar between each other. Carboxyl and methoxyl-ends lipid-polymer
NPs have negative charge whereas amine-ends lipid-polymer NPs have positive charge.
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Figure 2.
Human serum complement system activation of lipid-polymer hybrid NPs surface
functionalized with carboxyl (NP-COOH), methoxyl (NP-OCH3) and amine (NP-NH2)
groups, respectively. (A) Complement system activation at the terminal cascade. Bars represent
the mean concentration of SC5b-9, a sensitive biomarker of C5a formation via both the
alternative pathway and the classical pathway. The results were obtained from three
independent experiments with a 95% confidential interval. (B) Complement system activation
via the alternative pathway. Bb is the proteolytically active fragment of factor B, a biomarker
of the complement system activation via the alternative pathway. (C) Complement system
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activation via the classical pathway. C4d measures the amount of C4d-containing activation
fragments of C4, a biomarker of the complement system activation via the classical pathway.
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Figure 3.
Human serum complement system activation of lipid-polymer hybrid NPs with a mixture of
carboxyl and methoxyl surface groups. (A) SC5b-9 concentration and NP surface zeta potential
plotted as a function of carboxyl group and methoxyl group molar ratio (COOH/OCH3). (B)
Gel electrophoresis results of human serum proteins binding to the hybrid nanoparticles at
various COOH/OCH3 molar ratios.
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Figure 4.
Human serum complement system activation of lipid-polymer hybrid nanoparticles with a
mixture of carboxyl and amine surface groups. (A) SC5b-9 concentration and NP surface zeta
potential plotted as a function of carboxyl group and amine group molar ratio (COOH/NH2).
(B) Gel electrophoresis results of human serum proteins binding to the hybrid nanoparticles at
various COOH/NH2 molar ratios.
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Figure 5.
Human serum complement system activation of lipid-polymer hybrid NPs with a mixture of
amine and methoxyl surface groups. (A) SC5b-9 concentration and NP surface zeta potential
plotted as a function of amine group and methoxyl group molar ratio (NH2/OCH3). (B) Gel
electrophoresis results of human serum proteins binding to the hybrid NPs at various NH2/
OCH3 molar ratios.
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Figure 6.
Gel electrophoresis results of human plasma proteins binding to the lipid-polymer hybrid NPs
with a mixture of surface functional groups: (A) COOH/OCH3, (B) NH2/OCH3, and (C)
COOH/NH2.
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Table 1
Quantification of human serum proteins binding to lipid-polymer hybrid NPs with different surface functional groups.
The protein binding density, characteristic of integrated density value (IDV), was obtained by using the software of
the FluorCHEM quantitative imaging system (Alpha Innotech). For clarity reason, the IDVs of each protein binding
to NP-COOH, NP-NH2 and NP-OCH3 nanoparticles, respectively, were normalized to the IDV of NP-OCH3
nanoparticles. Smaller IDV number represents higher amount of protein binding to the NPs.
Human serum proteins COOH CH3O NH2
Amount of protein bound
Factor H 0.98 1 0.94
Complement component C6 precursor 1.02 1 0.86
Complement C1r subcomponent precursor 0.89 1 0.89
C3b β chain 0.97 1 0.98
Complement component C8α chain precursor 1.02 1 0.91
Apolipoprotein IV 0.72 1 0.87
Apolipoprotein E 0.80 1 0.84
Apolipoprotein AI 1.05 1 1.06
Serum amyloid A-4 protein precursor 0 1 0.92
Apolipoprotein C-III 1.01 1 0.95
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Table 2
Quantification of human serum proteins binding to lipid-polymer hybrid NPs with a mixture of carboxyl and methoxyl
surface groups (NP-COOH/OCH3). The numbers of 75/25, 50/50 and 25/75 represent the molar ratios of COOH/
OCH3.
Human serum proteins 75/25 50/50 25/75
Amount of protein bound
Factor H 0.73 1 0.91
Complement component C6 precursor 0.72 1 0.85
Complement C1r subcomponent precursor 0.70 1 0.80
C3b β chain 0.80 1 0.71
Complement component C8α chain precursor 0.68 1 0.95
Apolipoprotein IV 0.85 1 0.83
Apolipoprotein E 0.69 1 0.80
Apolipoprotein AI 1.20 1 0.95
Serum amyloid A-4 protein precursor - 1 -
Apolipoprotein C-III 0.77 1 0.86
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Table 3
Quantification of human serum proteins binding to lipid-polymer hybrid NPs with a mixture of carboxyl and amine
surface groups (NP-COOH/NH2). The numbers of 75/25, 50/50 and 25/75 represent the molar ratios of COOH/NH2.
Human serum proteins 75/25 50/50 25/75
Amount of protein bound
Factor H 0.82 1 1
Complement component C6 precursor 0.72 1 0.87
Complement C1r subcomponent precursor 0.79 1 1
C3b β chain 0.58 1 0.98
Complement component C8α chain precursor 0.72 1 1.04
Apolipoprotein IV 0.66 1 0.83
Apolipoprotein E 0.78 1 1.21
Apolipoprotein AI 2.08 1 3.71
Serum amyloid A-4 protein precursor - 1 -
Apolipoprotein C-III 0.85 1 0.96
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Table 4
Quantification of human serum proteins binding to lipid-polymer hybrid NPs with a mixture of amine and methoxyl
surface groups (NP-NH2/OCH3). The numbers of 75/25, 50/50 and 25/75 represent the molar ratios of NH2/OCH3.
Human serum proteins 75/25 50/50 25/75
Amount of protein bound
Factor H 0.73 1 0.80
Complement component C6 precursor 0.53 1 0.80
Complement C1r subcomponent precursor 0.92 1 0.87
C3b β chain 0.48 1 0.91
Complement component C8α chain precursor 0.47 1 0.76
Apolipoprotein IV 0.69 1 1.00
Apolipoprotein E 0.48 1 0.93
Apolipoprotein AI 0.42 1 0.92
Serum amyloid A-4 protein precursor 1.16 1 1.21
Apolipoprotein C-III 0.59 1 0.74
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Table 5
Quantification of human plasma proteins binding to lipid-polymer hybrid NPs with different surface functional groups.
Human plasma proteins COOH CH3O NH2
Amount of protein bound
Factor H 0.61 1 1.09
Complement component C6 precursor 1.10 1 1.17
Complement C1r subcomponent precursor 1.04 1 1.07
Fibrinogen α chain 0.83 1 1.18
Fibrinogen β chain 1.18 1 1.06
Fibrinogen γ chain 1.16 1 0.96
Apolipoprotein IV 1.31 1 1.27
Apolipoprotein E 1.22 1 1.05
Apolipoprotein AI 0.89 1 1.32
Serum amyloid A-4 protein precursor 1.06 1 1.03
Apolipoprotein C-III - 1 1.03
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